Abstract
Background: Autoimmune Lymphoproliferative Syndrome (ALPS) is a rare inherited disorder of lymphocyte apoptosis characterized by chronic non-malignant lymphadenopathy, splenomegaly, autoimmune cytopenias, and an increased risk of lymphoma. The diagnostic hallmark is expansion of double-negative T cells (DNTs: CD3+ TCRαβ+ CD4– CD8–). Reports from low and middle-income countries remain limited, and diagnosis is often delayed or missed. We present six pediatric cases from a single center in Pakistan, highlighting their clinical and laboratory findings, management, therapeutic responses, diagnostic challenges, and outcomes. Materials & Methods : This descriptive study presents an observational case series from the pediatric Haematology Oncology department at The Children’s Hospital, University of Child Health Sciences, Lahore, Pakistan. The medical records of six patients with clinical and immunological features consistent with ALPS were reviewed. Demographic, clinical, laboratory, genetic, and treatment data were collected. Results : Six children (median age of onset 8 months) were included. Splenomegaly and autoimmune cytopenias were present in all cases, while lymphadenopathy was seen in four. All had raised double-negative T cells. Corticosteroids showed limited benefit, whereas sirolimus achieved sustained remission in most patients. One child required a splenectomy for refractory thrombocytopenia. Conclusion : ALPS should be considered in the differential diagnosis of children presenting with non-malignant lymphadenopathy and unexplained cytopenia. This case series highlights the variable clinical spectrum of ALPS in children and emphasizes the diagnostic utility of clinical and immunologic features, along with double-negative T cells, in diagnosing ALPS. Early recognition and targeted therapy are critical to improve outcomes, particularly in resource-limited settings where genetic testing is not readily available.